Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
June 4, 2007
- OPINION／Would You Follow Someone Like You?
June 4, 2007
- NEJM Article on Avandia "Based on Incomplete Evidence": GSK
June 4, 2007
- R&D NEWS IN BRIEF
June 4, 2007
- REGULATORY NEWS IN BRIEF
June 4, 2007
- Korosho Has No Plan to Cut Initial/Repeat Consultation Fees: Korosho Officials
June 4, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 4, 2007
- Generics and Original Drugs Are Not the Same: Prof. Uchida
June 4, 2007
- SELF-MEDICATION NEWS IN BRIEF
June 4, 2007
- GENERIC NEWS IN BRIEF
June 4, 2007
- MEDICAL DEVICE NEWS IN BRIEF
June 4, 2007
- Mediceo Paltac: Sales Exceed \2 Tril. Mark
June 4, 2007
- SURVEY／Low Expectations for Treatment of ADHD in Japan: Eli Lilly
June 4, 2007
- Alfresa HD: Sales Up 12.6% to \1,590 Bil., Big Jump in Profits
June 4, 2007
- New JGPMA President H. Sawai Aims at 30% Share for Generics
June 4, 2007
- Suzuken: Sales Up 4.8% to \1,455 Bil.
June 4, 2007
- Four Major Wholesalers' Sales Up 10.2%, Operating Profits Up 32.8%
June 4, 2007
- Toho Pharm.: Sales Up 9.5%, Operating Profits Up 52.9%
June 4, 2007
- Korosho Proposes Switching to Generics to Lift Price Agreement Rate
June 4, 2007
- VITAL-NET: Aiming at Ordinary Profits-to-Sales Ratio of 2.2%
June 4, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…